Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties

On August 18, 2025 Philochem AG ("Philochem"), a wholly-owned subsidiary of Philogen company (MIL: PHIL), and RayzeBio, Inc. ("RayzeBio"), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), reported the successful completion of U.S. antitrust review and the closing of the global licensing agreement for OncoACP3, a clinical-stage therapeutic and diagnostic agent targeting prostate cancer (Press release, Philogen, AUG 18, 2025, View Source [SID1234655354]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The transaction, initially announced on June 10, 2025, has now been finalized following clearance under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 by the U.S. Federal Trade Commission (FTC). As part of the agreement, Philochem will receive an upfront payment of $350 million.

RayzeBio will be responsible for the development and any subsequent commercialization of OncoACP3. The license agreement also includes up to $1.0 billion in development, regulatory and commercial milestone payments, as well as mid-single to low double-digit royalties on global net sales.

"I am very pleased that we have received clearance, allowing us to proceed with this agreement with RayzeBio," said Dario Neri, CEO and CSO of Philogen. "They share our vision for revolutionizing the diagnosis and treatment of prostate cancer. We believe that OncoACP3 has all the credentials to become a breakthrough treatment for patients, translating scientific innovation into an important medical advance".

Ben Hickey, President, RayzeBio commented: "The closing of this agreement marks an important milestone for RayzeBio as we expand our leadership in the radiopharmaceuticals space. We look forward to advancing OncoACP3 for the benefit of patients, consistent with our strategy to bring forward best-in-class RPT candidates."